Douglas Minder was appointed CFO in July 2023. He joined Biotalys in January 2021 and was closely involved in the company's IPO on Euronext Brussels in July that year. Since then, he has lead the finance team and prepared for taking over the role of CFO.
Douglas has over 30 years of financial experience, which includes more than eight years at Belgium-based multinational biopharmaceutical company UCB. His most recent position there was Finance Business Partner, where he worked across many groups to help them align strategic objectives with the company’s long-range financial plans. He also worked for 20 years as an auditor and consultant at Deloitte, both in Belgium and in the U.S., where he served various Fortune 500 companies across multiple industries, including biopharma, technology, chemicals and manufacturing.
He is an expert in U.S. GAAP and IFRS standards and reporting requirements for both the U.S. and European markets and has built successful cross-departmental relationships to develop continuous improvement solutions throughout an organization.